Comparison Of Early-Stage High-Grade Serous Primary Fallopian Tube Cancers and Epithelial Ovarian Cancers: A Multicenter Study

Gungorduk K., Ozdemir A., Selcuk I., Telli E., Sahin O., Toptas T., ...Daha Fazla

ONCOLOGY RESEARCH AND TREATMENT, cilt.40, sa.4, ss.203-206, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 40 Sayı: 4
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1159/000458440
  • Dergi Adı: ONCOLOGY RESEARCH AND TREATMENT
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.203-206
  • Anahtar Kelimeler: Primary fallopian tube cancer, Epithelial ovarian cancer, High-grade serous cancer, CARCINOMA, ADENOCARCINOMA
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Introduction: We compared the disease free-survival (DFS) and overall survival (OS) rates of patients with high-grade serous primary fallopian tube cancer (HG-sPFTC) and high-grade serous epithelial ovarian cancer (HG-sEOC). Methods: 22 early-stage cancer patients (International Federation of Gynecology and Obstetrics (FIGO) stages I-II) with HG-sPFTC were retrospectively evaluated. In addition, 44 control patients diagnosed with HG-sEOC were matched to these patients with respect to tumor stage at diagnosis. All patients underwent complete surgical staging, followed by adjuvant chemotherapy. Kaplan-Meier curves were used to generate survival data. Results: The mean age of HG-sPFTC patients was 59.4 +/- 6.2 years, and that of HG-sEOC patients 55.2 +/- 11.0 years (p = 0.002). All patients underwent 6 cycles of platinum-based adjuvant chemotherapy. All operations were optimal. The 5-year DFSs were 77.3% for HG-sPFTC patients and 75% for HG-sEOC patients (p = 1.00).The 5-year OS rates were 81.8% in women with HG-sPFTC and 77.3% in those with HG-sEOC (p = 0.75). Conclusion: The DFS and OS rates of patients with early-stage (FIGO stages I and II) HG-sPFTC and HG-sEOC were similar. The surgical and adjuvant therapy management of these malignancies should be similar. (C) 2017 S. Karger GmbH, Freiburg